Daxor Posts 45% Revenue Growth on FDA Clearance, Eyes Break-Even

Event summary

  • Daxor's 2025 revenue rose 45% YoY, with operating loss narrowing to $268,598 from $1.6M prior year
  • FDA cleared next-gen Blood Volume Analyzer in August 2025, developed with DoD contract
  • Net asset value per share increased $1.82 to $9.07 as of December 31, 2025
  • Closed $9M capital raise in January 2026 at $11.75/share to fund commercialization
  • Plans to transition to Securities Exchange Act reporting framework

The big picture

Daxor's strong revenue growth reflects accelerating adoption of its blood volume measurement technology in critical care settings. The FDA clearance positions the company to compete more directly with traditional lab diagnostics, while the capital raise and reporting transition signal preparation for higher-growth phase. The medical diagnostics sector continues to favor precise, portable solutions that reduce hospital readmissions and treatment costs.

What we're watching

Commercialization Pace
How quickly Daxor can deploy next-gen analyzers and scale sales team to capitalize on FDA clearance
Path to Profitability
Whether operating loss improvements can continue as R&D and manufacturing investments peak
Regulatory Transition
Impact of Securities Exchange Act reporting on investor perception and comparability

Related topics

Diagnostics